
What We’re Reading: CMS Hospice Payment Rate Rule; COVID-19 Funding; FDA Votes on ALS Treatment
CMS-1773-P will establish a budget-neutral payment policy to smooth year-to-year changes in the hospice wage index; President Joe Biden pushes for $22 billion in COVID-19 funding from Congress; an FDA advisory panel said there is not enough evidence supporting the efficacy of the amyotrophic lateral sclerosis (ALS) treatment AMX0035.
CMS Proposes Hospice Payment Rate Rule for 2023 Fiscal Year
CMS proposed a new rule Wednesday that would provide routine adjustments to hospice-based payments and the aggregate cap amount for the 2023 fiscal year,
President Biden Fights for More COVID-19 Funding
As part of his announcement of COVID.gov, President Joe Biden also pushed for more COVID-19 funding from Congress,
FDA Panel Says New ALS Treatment Is Not Yet Proven Effective
An FDA advisory panel said there is not enough evidence supporting the efficacy of the new amyotrophic lateral sclerosis (ALS) treatment AMX0035, which was developed by Amylyx Pharmaceuticals,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.